Alicia Ciccone

The findings suggest that [F-18]FDDNP-PET imaging can be used to diagnose chronic traumatic encephalopathy in at-risk patients.

Cognitive dysfunction may be the result of lower intracerebral vasomotor reactivity which is linked to PHPT.

A first-of-its kind trial will explore the benefits of vagus nerve stimulation for stroke rehabilitation; plus, can a brain implant restore vision to the blind?

A hyped status epilepticus drug falls flat in phase 3; misconceptions about vaccines and autism influence health care decisions in siblings.

Fingolimod proves effective in pediatric patients with MS while radiologists face a future where technology may replace them.

The FDA denies a NDA for an up-and-coming Parkinson’s drug over manufacturing issues while researchers discover significant sex-specific differences in the brains of people with depression.

Austedo was previously approved for the treatment of chorea in Huntington’s disease.

Gocovri is the first treatment for dyskinesia approved for patients with Parkinson’s disease who are receiving levodopa therapy.

Will a mini-dystrophin gene be the key to treating muscular dystrophy? Plus, a recent recall of an epilepsy drug and updated practice guidelines.

MS drug makers are coming under fire for rapidly rising drug prices while another lawsuit is filed against Purdue Pharma for deceptive marketing practices for OxyContin.

Eli Lilly reports more positive phase 3 data for its acute migraine drug lasmiditan, while yet another brain-training company comes under fire for making baseless claims.

The NIH-NFL partnership for brain research is walking away from millions of unspent money. Plus, are girls better at masking autism symptoms?

FDA recalls Penumbra revascularization device while Amgen reaches the FDA first with its CGRP migraine drug erenumab.

Patients can receive the gammaCore device by participating in the gammaCore Patient Registry program.

Transporting neonates from the intensive care unit to MRI suites can pose challenges to care and patient safety.

Senator John McCain has been handed a grim neurological diagnosis. Plus, a new headache treatment is on the market.

State drug agencies face a new and growing threat in gabapentin abuse as the NIH battles through a brain tissue shortage.

Researchers say serotonin levels may be a biomarker of SIDS. Plus, new findings may help develop therapeutics that can better penetrate the blood-brain barrier.

Patients are facing major backlash from insurers refusing to cover the cost of a controversial Duchenne muscular dystrophy drug while the National Academies of Sciences are recommending steps to prevent dementia.

A large genomic study has identified 5 genes related to insomnia, plus hear from the DAWN trial investigators on the impact their data might have on the future of stroke treatment.

In a first, the FDA has requested the removal of an opioid medication from the market. Plus, is snake venom the latest antiplatelet agent?

Nearly 40% of patients in the treatment group were “much” or “very much” improved at 4 weeks.

Patients who underwent deep brain stimulation were 94% less likely to require polypharmacy at 5 years.

Patients with metabolic syndrome experienced greater worsening of UPDRS scores over time compared with patients without metabolic syndrome.

Previous research has shown that plasma neurofilament light chain concentration may predict severity of disease progression in progressive supranuclear palsy.

While polyneuropathy is fairly common in Parkinson’s disease, the etiology of the pain condition is not clear.

Researchers sought to better understand the potential role of cholesterol in the etiology of Parkinson’s disease.

New research suggests that ketamine may do more harm than good when it comes to preventing delirium, plus is an old, cheap, generic drug about to be repurposed for another neurologic disorder?

Joohi Jimenez-Shahed, MD, discusses her research on the use of deutetrabenazine for the treatment of tardive dyskinesia in patients taking concomitant antipsychotics or neuroleptics. Scroll below the video for the full transcript.

The post-hoc analysis sought to identify factors predictive of relapse and disability progression in people with MS enrolled in the TRANSFORMS study.